AdAlta Ltd (ASX:1AD) CEO Tim Oldham discusses with Proactive the latest developments with its next generation i-body enabled Chimeric Antigen Receptor (CAR)-T cell therapy technology platform as well as what’s coming up for the company’s lead product candidate AD-214. He says there’ll be a number of important data read-outs across its portfolio of programs during 2023.
AdAlta CEO highlights strong progress across CAR-T and AD-214 programs
